NIMULID SUSPENSION 50MG/5ML 60ML
NIMULID SUSPENSION 50MG/5ML 60ML - 1BOTTLE
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
5 ml contain Nimesulide 50 mg;
other ingredients: xanthine, sorbitol solution, glycerol, polyoxyl 40 hydrogenated with castor oil, sodium methylhydroxybenzoate, sodium propylhydroxybenzoate, sodium benzoate, colloidal silicon dioxide, sucrose, sodium metabisulfate, citric acid monohydrate, concentrated hydrochloric acid, quinoline, sodium saharamidium sulfate, sodium citrate, citric acid monohydrate, concentrated hydrochloric acid, quinoline, sodium, sodium, sodium, sodium, sodium, sodium, sodium, sodium, sodium citrate, citric acid monohydrate, citric acid distilled
Bottle of 60 ml.
Mechanism of action
NSAIDs sulfonanilide class. Selective inhibitor of COX-2. It has anti-inflammatory, analgesic and antipyretic effects.
The mechanism of action is associated with inhibition of prostaglandin synthesis. Inhibits the synthesis of prostaglandins by inhibiting COX-2. Suppresses platelet activation factor, tumor necrosis factor alpha, synthesis of proteinases and histamine.
Indications and usage
- rheumatoid arthritis;
- osteoarthritis, osteoarthritis;
- tendonitis, tenosynovit;
- as a symptomatic therapy in the treatment of inflammatory processes accompanied by pain and fever (in the postoperative period, for injuries, back pain, for diseases of the ear, nose and throat / includingpharyngitis, tonsillitis, otitis /, with injuries and injuries of soft tissues, with injuries of the musculoskeletal system, in dentistry / including toothache /, in gynecology);
- symptoms of fever and inflammation associated with infections of the upper respiratory tract (viral or bacterial etiology).
- erosive and ulcerative lesions of the gastrointestinal tract in the acute phase;
- severe liver dysfunction;
- pronounced renal dysfunction;
- lactation (breastfeeding);
- hypersensitivity to nimesulide and other components of the drug, Acetylsalicylic acid and other NSAIDs.
Pregnancy and Breastfeeding
ATexperimental studies in animals treated with oral Nimulid, no teratogenic effects were observed.
It should be noted, however, that currently there are no data on the safety of nimesulide in pregnant and lactating women, and therefore the drug Nimulid for oral administration and in the form of a transdermal gel is not recommended for pregnant and lactating women.
Dosage and administration
Children Nimulid prescribed in the form of a suspension for oral administration in a dose of 1.5 mg / kg body weight 2-3 times / day. The maximum dose for children - 5 mg / kg / day, divided into 2-3 doses.
Gastrointestinal: epigastric discomfort, nausea, vomiting, stomach pain, diarrhea.
From the side of the central nervous system: dizziness, headache, drowsiness.
Allergic reactions: itching, urticaria, bronchospasm.
Local reactions: rarely - irritation, erythema, skin rash, peeling, itching (at the site of application of the gel); sometimes transient discoloration of the skin.
Care should be taken when prescribing the drug to patients with congestive heart failure, arterial hypertension, visual impairment and impaired liver and / or kidney function.
If local irritation occurs when using Nimulid in the form of a transdermal gel, its use should be stopped and, if necessary, appropriate treatment should be given.
Nimulid in the form of a transdermal gel should be avoided in the eyes, mucous membranes, as well as skin areas affected by dermatoses or infections.
When using transdermal gel, it is possible to stain the laundry.
Care should be taken with simultaneous use of the drug Nimulid with Digoxin, phenytoin, lithium preparations, diuretics, antihypertensive drugs, other NSAIDs, anticoagulants, cyclosporine, Methotrexate, oral hypoglycemic agents.
Influence on ability to drive motor transport and control mechanisms
The drug may cause drowsiness or dizziness, which should be taken into account for patients engaged in potentially hazardous activities that require increased attention and quickness of psychomotor reactions.
With simultaneous use with Nimulid enhanced effects of drugs that reduce blood clotting.
With simultaneous use Nimulid increases the concentration of lithium in the blood plasma.
At a temperature not higher than 25 ° С.